NCT05992688

Brief Summary

This is an 8 to14-week three-arm randomized controlled in children 8 to 12 years old. The main purpose of the study is to evaluate if stevia has benefits for weight control and metabolic function relative to caloric sweeteners, and whether it provides benefits in this regard similar to water.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
7mo left

Started Sep 2023

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress82%
Sep 2023Nov 2026

First Submitted

Initial submission to the registry

August 8, 2023

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 15, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

September 19, 2023

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2026

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2026

Last Updated

December 22, 2025

Status Verified

December 1, 2025

Enrollment Period

2.7 years

First QC Date

August 8, 2023

Last Update Submit

December 16, 2025

Conditions

Keywords

Cardiometabolic health

Outcome Measures

Primary Outcomes (5)

  • Body mass index (BMI) z-scores

    The change in BMI z-score will be calculated: BMI z-score at completion of the study minus BMI z-score at baseline

    Measurements will be obtained at enrollment (baseline) and again at weeks 4 and 8 for all participants. Children with excessive weight will also complete an additional assessment at week 14.

  • Fat mass index z-scores

    The change in fat mass index (FMI) z-score will be calculated: FMI z-score at completion of the study minus FMI z-score at baseline.

    Measurements will be obtained at enrollment (baseline) and again at weeks 4 and 8 for all participants. Children with excessive weight will also complete an additional assessment at week 14.

  • Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

    HOMA-IR is a unitless estimate of insulin resistance, and it is calculated from fasting glucose and insulin

    Measurements will be obtained at enrollment (baseline) and again at weeks 4 and 8 for all participants. Children with excessive weight will also complete an additional assessment at week 14.

  • Fasting plasma lipids (Total cholesterol, HDL-cholesterol, triglycerides, LDL-cholesterol)

    Fasting plasma lipids, mg/dl

    Measurements will be obtained at enrollment (baseline) and again at weeks 4 and 8 for all participants. Children with excessive weight will also complete an additional assessment at week 14.

  • Blood pressure percentiles

    Systolic and diastolic blood pressure percentiles calculated using reference standards from the American Academy of Pediatrics.

    Measurements will be obtained at enrollment (baseline) and again at weeks 4 and 8 for all participants. Children with excessive weight will also complete an additional assessment at week 14.

Secondary Outcomes (1)

  • Gut microbial communities

    Measurements will be obtained at enrollment (baseline) and again at week 8 for all participants. Children with excessive weight will also complete an additional assessment at week 14.

Study Arms (3)

Sucrose sweetened beverage

ACTIVE COMPARATOR

Sucrose (i.e. sugar): 31.2 g sugar (124.8 Kcal per serving). Participants will be asked to consume the study product once a day for 8 to 14 weeks if they have normal weight or excessive weight, respectively.

Other: Sucrose sweetened beverage

Stevia sweetened beverage

EXPERIMENTAL

The stevia-sweetened beverage contains 48.6 mg of steviol equivalents. Participants will be asked to consume the study product once a day for 8 to 14 weeks if they have normal weight or excessive weight, respectively.

Other: Stevia sweetened beverages

Calorie free flavored water beverage

ACTIVE COMPARATOR

Flavored water. Participants will be asked to consume the study product once a day for 8 to 14 weeks if they have normal weight or excessive weight, respectively.

Other: Calorie free flavored water beverage

Interventions

Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 14 weeks.

Sucrose sweetened beverage

Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 14 weeks.

Stevia sweetened beverage

Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 14 weeks.

Calorie free flavored water beverage

Eligibility Criteria

Age8 Years - 12 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Age 8-12 years
  • Normal weight: BMI percentile ≥5th to \<85th
  • Excessive weight: BMI percentile ≥ 85th and \<140% of the 95th percentile or BMI ≥35 to \<40 kg/m2
  • Current consumption of sugar sweetened beverages (≥2 times /wk)
  • Low consumption of non-nutritive sweeteners (≤ 3 time/wk)

You may not qualify if:

  • Children with class 3 obesity (i.e., BMI ≥ 140% of the 95th percentile or BMI ≥ 40.0 kg/m2)
  • Dislike of experimental beverage taste (assessed at initial visit)
  • Asthma that requires daily use of inhalers to keep symptoms under control.
  • Asthma that requires use of rescue inhalers (e.g., albuterol) \>2 days per week
  • Exercise induced asthma.
  • Autism spectrum disorder (e.g., Autistic disorder, Rett disorder, Asperger disorder, childhood disintegrative disorder, pervasive developmental disorder not otherwise specified (PDD-NOS).
  • Attention deficit hyperactivity disorder (ADHD) currently under medication.
  • Oppositional defiant disorder (ODD).
  • Epilepsy.
  • Cancer.
  • Chronic kidney disease.
  • Endocrine disorder (e.g., hypothyroidism and growth hormone deficiency).
  • Autoimmune diseases (e.g., lupus, thyroiditis, juvenile idiopathic arthritis)
  • Bleeding disorders (e.g., hemophilia)
  • Chronic infections (e.g., HIV, hepatitis B, hepatitis C).
  • +8 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Arkansas Children's Nutrition Center

Little Rock, Arkansas, 72202, United States

RECRUITING

Arkansas Children's Nutrition Center

Little Rock, Arkansas, 72202, United States

RECRUITING

MeSH Terms

Conditions

ObesityInsulin ResistanceWeight Gain

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesBody Weight Changes

Study Officials

  • Eva Diaz, M.D.

    Arkansas Children's Nutrition Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Eva C Diaz, M.D.

CONTACT

Mario Ferruzzi, Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 8, 2023

First Posted

August 15, 2023

Study Start

September 19, 2023

Primary Completion (Estimated)

May 31, 2026

Study Completion (Estimated)

November 30, 2026

Last Updated

December 22, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

All study subject materials will be assigned a unique identifying code or number. The key to the code will be kept in a shared network folder with access granted only to study staff who have had appropriate CITI training. Only study investigators/staff will have access to the code and information that identifies the subject in this study. Coded data for all primary and secondary outcomes as well as secondary data analysis will be shared with the Sponsor (Cargill Corporation) using an approved shared folder .

Locations